Nature, Published online: 06 August 2025; doi:10.1038/s41586-025-09299-y

A highly potent and selective small-molecule catalytic inhibitor of the protein lysine methyltransferase NSD2 shows therapeutic efficacy in preclinical models of KRAS-driven pancreatic cancer and lung cancer.